

Gian Marco Conte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443512/publications.pdf>

Version: 2024-02-01

25
papers

481
citations

759233

12
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

796
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. <i>European Journal of Radiology</i> , 2016, 85, 1147-1156.	2.6	76
2	Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images. <i>Radiology</i> , 2018, 287, 933-943.	7.3	70
3	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. <i>Radiology</i> , 2021, 299, 313-323.	7.3	46
4	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- α in primary CNS lymphoma. <i>Blood</i> , 2019, 134, 252-262.	1.4	43
5	SOUP-GAN: Super-Resolution MRI Using Generative Adversarial Networks. <i>Tomography</i> , 2022, 8, 905-919.	1.8	40
6	Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 149.	3.0	38
7	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658.	5.2	24
8	Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software. <i>Radiologia Medica</i> , 2017, 122, 294-302.	7.7	23
9	Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas. <i>European Radiology</i> , 2019, 29, 3467-3479.	4.5	22
10	Complete abdomen and pelvis segmentation using U-Net variant architecture. <i>Medical Physics</i> , 2020, 47, 5609-5618.	3.0	17
11	Fully Automated Segmentation of Head CT Neuroanatomy Using Deep Learning. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190183.	5.8	15
12	18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy. <i>Clinical Nuclear Medicine</i> , 2017, 42, e525-e526.	1.3	13
13	Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness. <i>European Journal of Radiology</i> , 2021, 143, 109945.	2.6	12
14	Integration of Diffusion Magnetic Resonance Tractography into tomotherapy radiation treatment planning for high-grade gliomas. <i>Physica Medica</i> , 2018, 55, 127-134.	0.7	11
15	Hypoxia 18F-FAZA PET/CT imaging in lung cancer and high-grade glioma: open issues in clinical application. <i>Clinical and Translational Imaging</i> , 2017, 5, 389-397.	2.1	9
16	18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers. <i>Nuclear Medicine Communications</i> , 2021, 42, 763-771.	1.1	6
17	Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients. <i>Current Research in Immunology</i> , 2021, 2, 155-162.	2.8	4
18	Persistent homology approach distinguishes potential pattern between "Early" and "Not Early" hepatic decompensation groups using MRI modalities. <i>Current Directions in Biomedical Engineering</i> , 2021, 7, 488-491.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Abstract PO-023: Differentiation of tumefactive multiple sclerosis and glioblastoma using radiomics features extracted from magnetic resonance imaging and machine learning. , 2021, , .		1
20	Endocannabinoid Response in Acute Ischemic Stroke. Stroke, 2021, 52, e131-e132.	2.0	1
21	R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the "INGRID" phase II trial.. Journal of Clinical Oncology, 2018, 36, 7575-7575.	1.6	0
22	R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial. Blood, 2018, 132, 1687-1687.	1.4	0
23	Ceramide Dynamics and Prognostic Value in Acute and Subacute Ischemic Stroke: Preliminary Findings in a Clinical Cohort. Journal of Neurology Research, 2020, 10, 209-219.	0.5	0
24	Blood-Brain Barrier Permeabilization with Engineered Tumor Necrosis Factor- α Followed by R-CHOP Is an Active and Safe Salvage Therapy in Primary CNS Lymphoma. SSRN Electronic Journal, 0, , .	0.4	0
25	EPID-18. USING GERMLINE VARIANTS FOR DIFFERENTIAL DIAGNOSIS OF INDETERMINATE BRAIN LESIONS: EVALUATING THE EFFECT OF TUMOR TYPE AND RACE ON SENSITIVITY AND SPECIFICITY OF GLIOMA polygenic risk models. Neuro-Oncology, 2021, 23, vi89-vi89.	1.2	0